Seek Returns

GILD vs. LLY: Gilead Sciences vs. Eli Lilly Stock Comparison

How do Gilead Sciences (GILD) and Eli Lilly (LLY) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Gilead Sciences (GILD) and Eli Lilly (LLY) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but GILD is classified in Biotechnology while LLY is classified in Pharmaceuticals.

Company profile comparison for Gilead Sciences (GILD) and Eli Lilly (LLY)
Profile ItemGILDLLY
NameGilead Sciences Inc.Eli Lilly and Company
Country/RegionUnited StatesUnited States
GICS SectorHealth CareHealth Care
GICS Industry GroupPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnologyPharmaceuticals
GICS Sub-IndustryBiotechnologyPharmaceuticals
Market Capitalization207.00 billion USD1,206.07 billion USD
CurrencyUSDUSD
ExchangeNasdaqNYSE
Listing DateJanuary 22, 1992June 1, 1972
Security TypeCommon StockCommon Stock

Price Performance

Cumulative Growth

GILD
LLY
GSPC
Loading price history…
Gilead Sciences (GILD) vs. Eli Lilly (LLY), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…
Trailing total returns for Gilead Sciences (GILD) and Eli Lilly (LLY). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…
Calendar-year total returns for Gilead Sciences (GILD) and Eli Lilly (LLY). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Gilead Sciences (GILD) and Eli Lilly (LLY)
MetricGILDLLY
Total Return (1Y)45.69%52.36%
Total Return (3Y, Annualized)35.30%34.18%
Total Return (5Y, Annualized)25.00%41.08%

Risk Profile

Drawdown History

GILD
LLY
GSPC
Loading price history…
Gilead Sciences (GILD) vs. Eli Lilly (LLY), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…
Distribution of monthly total returns for Gilead Sciences (GILD) and Eli Lilly (LLY). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Gilead Sciences (GILD) and Eli Lilly (LLY)
MetricGILDLLY
Volatility (1Y, Annualized)27.57%35.34%
Beta (5Y)0.360.40
Max Drawdown (5Y)-26.59%-34.48%
Avg. Volume (3M)5.98M2.52M

Risk-Adjusted Performance

Risk-Return Positioning

Loading chart…
GILD and LLY are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Gilead Sciences (GILD) and Eli Lilly (LLY)
MetricGILDLLY
Sharpe Ratio (1Y)1.501.36
Sortino Ratio (1Y)2.482.29

Profitability

ROE (TTM)

Gilead Sciences (GILD) reports a negative ROE of -22.45%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Eli Lilly (LLY) reports 86.02%, ranking against industry peers normally.

GILD

Pharmaceuticals, Biotechnology & Life Sciences industry group

-22.45%

Max
109.18%
Q3
6.23%
GILD
-22.45%
Median
-26.66%
Q1
-64.05%
Min
-167.77%

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

86.02%

Max
109.18%
LLY
86.02%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
Min
-167.77%
Loading chart…
Gilead Sciences (GILD) vs. Eli Lilly (LLY): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Gilead Sciences (GILD) reports a negative net margin of -12.46%, usually indicating a net loss over the period. Meanwhile Eli Lilly (LLY) reports 31.90%, ranking against industry peers normally.

GILD

Pharmaceuticals, Biotechnology & Life Sciences industry group

-12.46%

Max
18.05%
Q3
4.78%
Median
0.00%
Q1
-4.14%
GILD
-12.46%
Min
-17.05%

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

31.90%

LLY
31.90%
Max
18.05%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%
Loading chart…
Gilead Sciences (GILD) vs. Eli Lilly (LLY): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Both Gilead Sciences (GILD) at 42.43% and Eli Lilly (LLY) at 53.66% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

GILD

Pharmaceuticals, Biotechnology & Life Sciences industry group

42.43%

Max
83.12%
GILD
42.43%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

53.66%

Max
83.12%
LLY
53.66%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%
Loading chart…
Gilead Sciences (GILD) vs. Eli Lilly (LLY): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Gilead Sciences (GILD) and Eli Lilly (LLY)
MetricGILDLLY
ROE (TTM)-22.45%86.02%
ROA (TTM)13.47%21.06%
Net Margin (TTM)-12.46%31.90%
Operating Margin (TTM)42.43%53.66%
Gross Margin (TTM)79.95%83.63%

Growth

Revenue Growth

Both Gilead Sciences (GILD) at 2.39% and Eli Lilly (LLY) at 44.70% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Loading chart…
Gilead Sciences (GILD) vs. Eli Lilly (LLY): A comparison of their Revenue Growth across different time periods.

EPS Growth

Both companies show strong earnings momentum, but Gilead Sciences (GILD) at 1,684.21% is the standout with EPS growth above its industry range; Eli Lilly (LLY) at 95.99% also sits in the top quartile.

Loading chart…
Gilead Sciences (GILD) vs. Eli Lilly (LLY): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Gilead Sciences (GILD) and Eli Lilly (LLY)
MetricGILDLLY
Revenue Growth (YoY)2.39%44.70%
Revenue Growth (3Y CAGR)2.57%31.69%
EPS Growth (YoY)1,684.21%95.99%
EPS Growth (3Y CAGR)23.04%51.71%

Financial Strength

Current Ratio (MRQ)

Both Gilead Sciences (GILD) at 1.38 and Eli Lilly (LLY) at 1.39 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

GILD

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.38

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
GILD
1.38
Min
0.10

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.39

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
LLY
1.39
Min
0.10
Loading chart…
Gilead Sciences (GILD) vs. Eli Lilly (LLY): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Both balance sheets lean debt-heavy versus peers, but GILD is more stretched: Eli Lilly (LLY) at 1.23 sits in the higher-leverage quartile and Gilead Sciences (GILD) at 2.02 is above its industry benchmark range.

GILD

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.02

GILD
2.02
Max
1.42
Q3
0.65
Median
0.15
Q1
0.02
Min
0.00

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.23

Max
1.42
LLY
1.23
Q3
0.65
Median
0.15
Q1
0.02
Min
0.00
Loading chart…
Gilead Sciences (GILD) vs. Eli Lilly (LLY): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Gilead Sciences (GILD) and Eli Lilly (LLY)
MetricGILDLLY
Current Ratio (MRQ)1.381.39
Debt / Equity (MRQ)2.021.23
Net Debt / EBITDA1.250.96

Dividends

Dividend Yield (TTM)

Both Gilead Sciences (GILD) at 1.94% and Eli Lilly (LLY) at 0.49% yield above their industries’ entire benchmark ranges — high enough that dividend safety, not income, becomes the first question.

GILD

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.94%

GILD
1.94%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.49%

LLY
0.49%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Gilead Sciences (GILD) vs. Eli Lilly (LLY): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Both Gilead Sciences (GILD) at 43.46% and Eli Lilly (LLY) at 21.71% pay out more of their earnings than any of their industry peers — the thinnest cover in their groups, so dividend headroom deserves attention.

GILD

Pharmaceuticals, Biotechnology & Life Sciences industry group

43.46%

GILD
43.46%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

21.71%

LLY
21.71%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Gilead Sciences (GILD) vs. Eli Lilly (LLY): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Gilead Sciences (GILD) and Eli Lilly (LLY)
MetricGILDLLY
Dividend Yield (TTM)1.94%0.49%
Dividend Payout Ratio (TTM)43.46%21.71%

Valuation

P/E Ratio (TTM)

An earnings multiple is available for just one side: Eli Lilly (LLY) trades at 43.95 times trailing earnings, ranked against its peers, while Gilead Sciences (GILD) has no P/E ratio this period.

GILD

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
85.34
Q3
43.46
Median
26.69
Q1
13.30
Min
0.07
GILD
--

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

43.95

Max
85.34
LLY
43.95
Q3
43.46
Median
26.69
Q1
13.30
Min
0.07
Loading chart…
Gilead Sciences (GILD) vs. Eli Lilly (LLY): GILD does not report P/E ratio, so it has no value marker; LLY is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

P/S Ratio (TTM)

On P/S ratio, both Gilead Sciences (GILD) at 6.68 and Eli Lilly (LLY) at 13.95 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

GILD

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.68

Max
58.18
Q3
25.77
Median
7.30
GILD
6.68
Q1
3.01
Min
0.01

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

13.95

Max
58.18
Q3
25.77
LLY
13.95
Median
7.30
Q1
3.01
Min
0.01
Loading chart…
Gilead Sciences (GILD) vs. Eli Lilly (LLY): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Measured against book value, both Gilead Sciences (GILD) at 15.88 and Eli Lilly (LLY) at 29.96 look expensive — each P/B ratio sits above its industry’s benchmark range.

GILD

Pharmaceuticals, Biotechnology & Life Sciences industry group

15.88

GILD
15.88
Max
13.53
Q3
6.54
Median
3.25
Q1
1.69
Min
-5.59

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

29.96

LLY
29.96
Max
13.53
Q3
6.54
Median
3.25
Q1
1.69
Min
-5.59
Loading chart…
Gilead Sciences (GILD) vs. Eli Lilly (LLY): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Gilead Sciences (GILD) and Eli Lilly (LLY)
MetricGILDLLY
P/E Ratio (TTM)--43.95
P/S Ratio (TTM)6.6813.95
P/B Ratio (MRQ)15.8829.96
Free Cash Flow Yield (TTM)5.16%0.77%